{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:20:27Z","timestamp":1787916027299,"version":"build-2784847793"},"reference-count":36,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Swiss National Fund","award":["33IC30_193065"],"award-info":[{"award-number":["33IC30_193065"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,7,26]]},"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      <jats:italic>Clostridioides difficile<\/jats:italic>\n                      infection (CDI) is a leading cause of healthcare-associated diarrhoea in adults, with recurrence rates of 15%\u201325% after a first episode and up to 65% after multiple recurrences. Recurrent CDI leads to significant morbidity, diminished quality of life, prolonged antimicrobial exposure and increased healthcare utilisation. Faecal microbiota transplantation (FMT) demonstrates high efficacy for multiple recurrent CDI, but its benefit when used earlier\u2014after the first episode in high-risk patients or first recurrence\u2014remains insufficiently studied. Emerging evidence suggests early FMT may improve sustained clinical cure rates and reduce recurrence. This trial evaluates whether early introduction of oral FMT following standard therapy improves outcomes compared with standard therapy alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This is a multicentre, randomised, open-label, pragmatic phase III superiority clinical trial conducted across eight Swiss clinical centres. A total of 100 adults will be enrolled. Patients with either (1) a first CDI episode and risk factors for recurrence or (2) a first CDI recurrence and who first receive the real-world standard of care anti-CDI antibiotics (10 days of vancomycin or fidaxomicin) are randomised 1:1 to oral FMT following standard antibiotic therapy or standard therapy alone. The intervention group receives within 12\u2009hours to 4\u2009days of the last antibiotics administration, 15 to 20\u2009oral FMT capsules twice on two consecutive days if the CDI is non-severe; those with severe CDI receive an additional 2-day FMT course. The control group does not receive any additional treatment after completing the 10 days of standard therapy. The primary endpoint is the proportion of patients having experienced a CDI recurrence at 8 weeks post completion of treatment (assessed per-protocol and intention-to-treat). Secondary outcomes include early and late recurrence rates, sustained cure at 6 and 12 months, quality-adjusted life years, recurrence-free and overall survival at 12 months. Exploratory analyses include microbiota diversity, biomarker identification and assessment of immunologic and microbial predictors of recurrence. Safety\/tolerability is also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study will be conducted in accordance with International Council for Harmonisation Good Clinical Practice, the Declaration of Helsinki and Swiss regulatory standards. Results will be disseminated through peer-reviewed publications and conference presentations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05266807\">NCT05266807<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-119480","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:05:42Z","timestamp":1787915142000},"page":"e119480","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Fecal microbiota transplantation versus vancomycin or fidaxomicin in\n                    <i>Clostridioides difficile<\/i>\n                    infection first episode and first recurrence: a study protocol for a randomised, controlled, open-label, multicentre phase III clinical trial"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05266807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05266807","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tatiana","family":"Galp\u00e9rine","sequence":"first","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Erard","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Hopital Fribourgeois, Fribourg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-6878","authenticated-orcid":false,"given":"Rami","family":"Sommerstein","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner C","family":"Albricht","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Infection Prevention and Travel Medicine, St Gallen Cantonal Hospital, HOCH Health Ostschweiz, St. Gallen, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthaios","family":"Papadimitriou-Olivgeris","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"},{"name":"Infectious Diseases Service, Hospital of Valais, Institut Central des H\u00f4pitaux, Sion, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gubler","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, University of Bern, Inselspital University Hospital Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9492-9088","authenticated-orcid":false,"given":"Silvio D","family":"Brugger","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hospital Epidemiology, University of Zurich, University Hospital Zurich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tschudin-Sutter","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Clinical Research, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Moser","sequence":"additional","affiliation":[{"name":"Clinical Research Center (CRC), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4831-5158","authenticated-orcid":false,"given":"Laurene","family":"Cagnon","sequence":"additional","affiliation":[{"name":"Clinical Research Center (CRC), Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Ballif","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Becker","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Moser","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6526-0714","authenticated-orcid":false,"given":"Benoit","family":"Guery","sequence":"additional","affiliation":[{"name":"Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2026082804051439000_16.8.e119480.1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00016-13"},{"key":"2026082804051439000_16.8.e119480.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1505197"},{"key":"2026082804051439000_16.8.e119480.3","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.46.20316-en","article-title":"The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use","volume":"17","author":"Zarb","year":"2012","journal-title":"Euro Surveill"},{"key":"2026082804051439000_16.8.e119480.4","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.46.1800516","article-title":"Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017","volume":"23","author":"Suetens","year":"2018","journal-title":"Euro Surveill"},{"key":"2026082804051439000_16.8.e119480.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408913"},{"key":"2026082804051439000_16.8.e119480.6","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.398"},{"key":"2026082804051439000_16.8.e119480.7","doi-asserted-by":"publisher","DOI":"10.3201\/eid2210.151492"},{"key":"2026082804051439000_16.8.e119480.8","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12758"},{"key":"2026082804051439000_16.8.e119480.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.12.024"},{"key":"2026082804051439000_16.8.e119480.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1403772"},{"key":"2026082804051439000_16.8.e119480.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4609","article-title":"Clostridioides difficile: diagnosis and treatments","volume":"366","author":"Guery","year":"2019","journal-title":"BMJ"},{"key":"2026082804051439000_16.8.e119480.12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/1469-0691.12046","article-title":"Can we identify patients at high risk of recurrent Clostridium difficile infection?","volume":"18 Suppl 6","author":"Kelly","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026082804051439000_16.8.e119480.13","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1085"},{"key":"2026082804051439000_16.8.e119480.14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27 Suppl 2","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"2026082804051439000_16.8.e119480.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"2026082804051439000_16.8.e119480.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70374-7"},{"key":"2026082804051439000_16.8.e119480.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205037"},{"key":"2026082804051439000_16.8.e119480.18","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13144"},{"key":"2026082804051439000_16.8.e119480.19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab549"},{"key":"2026082804051439000_16.8.e119480.20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.01.008"},{"key":"2026082804051439000_16.8.e119480.21","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2020.1810531","article-title":"Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridioides difficile infection and beyond: the contribution of gut microbial-derived metabolites","volume":"12","author":"Martinez-Gili","year":"2020","journal-title":"Gut Microbes"},{"key":"2026082804051439000_16.8.e119480.22","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix762"},{"key":"2026082804051439000_16.8.e119480.23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S2468-1253(22)00276-X","article-title":"Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial","volume":"7","author":"Baunwall","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026082804051439000_16.8.e119480.24","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7326\/ANNALS-24-03285","article-title":"Fecal Microbiota Transplantation Versus Vancomycin for Primary Clostridioides difficile Infection\u202f: A Randomized Controlled Trial","volume":"178","author":"Juul","year":"2025","journal-title":"Ann Intern Med"},{"key":"2026082804051439000_16.8.e119480.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2026082804051439000_16.8.e119480.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103300","article-title":"Advocating for the recognition of underlying immunosuppression in critical illness","volume":"85","author":"Martin-Loeches","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026082804051439000_16.8.e119480.27","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/cid\/cis356","article-title":"Predictors of first recurrence of Clostridium difficile infection: implications for initial management","volume":"55 Suppl 2","author":"Eyre","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026082804051439000_16.8.e119480.28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10096-015-2549-9","article-title":"First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis","volume":"35","author":"Larrainzar-Coghen","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026082804051439000_16.8.e119480.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189227","article-title":"National epidemiology of initial and recurrent Clostridium difficile infection in the Veterans Health Administration from 2003 to 2014","volume":"12","author":"Reveles","year":"2017","journal-title":"PLoS One"},{"key":"2026082804051439000_16.8.e119480.30","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-024-09218-y","article-title":"Epidemiological and clinical burden of Clostridioides difficile infections and recurrences between 2015\u2009-\u20092019: the RECUR Germany study","volume":"24","author":"Tricotel","year":"2024","journal-title":"BMC Infect Dis"},{"key":"2026082804051439000_16.8.e119480.31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijid.2024.01.002","article-title":"Clostridioides difficile infections, recurrences, and clinical outcomes in real-world settings from 2015 to 2019: The RECUR England study","volume":"140","author":"Ghosh","year":"2024","journal-title":"Int J Infect Dis"},{"key":"2026082804051439000_16.8.e119480.32","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10096-025-05278-3","article-title":"Safety and efficacy of fecal microbiota transplantation versus antibiotics for treating clostridioides difficile infection: systematic review and meta-analysis","volume":"45","author":"Bhat","year":"2026","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026082804051439000_16.8.e119480.33","article-title":"Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile)","volume":"4","author":"Minkoff","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"2026082804051439000_16.8.e119480.34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/MCG.0000000000001610","article-title":"Fecal Microbiota Transplantation and Medical Therapy for Clostridium difficile Infection","volume":"56","author":"Singh","year":"2022","journal-title":"J Clin Gastroenterol"},{"key":"2026082804051439000_16.8.e119480.35","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cgh.2024.05.038","article-title":"Real-world Effectiveness of Fecal Microbiota Transplantation for First or Second Clostridioides difficile Infection","volume":"23","author":"Paaske","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026082804051439000_16.8.e119480.36","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/cid\/ciac207","article-title":"Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection","volume":"75","author":"Aby","year":"2022","journal-title":"Clin Infect Dis"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-119480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:05:45Z","timestamp":1787915145000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-119480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1136\/bmjopen-2026-119480"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-119480","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]}}}